Apr 24 |
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
|
Apr 22 |
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
|
Apr 17 |
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
|
Apr 11 |
3 Pharma Stocks to Sell in April Before They Crash & Burn
|
Apr 10 |
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
|